BMC Cancer最新文献

{"title":"Retraction Note: Sigma-2 receptor/TMEM97 agonist PB221 as an alternative drug for brain tumor.","authors":"Chia-Chi Liu, Ching-Fang Yu, Shu-Chi Wang, Hsueh-Yin Li, Chiu-Min Lin, Hsia-Han Wang, Carmen Abate, Chi-Shiun Chiang","doi":"10.1186/s12885-026-16727-3","DOIUrl":"https://doi.org/10.1186/s12885-026-16727-3","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13474577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148764939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development.","authors":"Hongjuan Chai, Chunpeng Pan, Mingyang Zhang, Haizhong Huo, Haiyan Shan, Jugang Wu","doi":"10.1186/s12885-026-16734-4","DOIUrl":"https://doi.org/10.1186/s12885-026-16734-4","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13474589/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single-cell analysis reveals the potential immunoregulatory role of C3 + malignant cell subpopulations in dedifferentiated liposarcoma.","authors":"Shengyun Hu, Yatong Dang, Baojing Tuo, Senbo Liu, Zhiyong Zhang, Lin Gan, Xiaoqing Gao, Mengmeng Xiao, Junhong Hu, Zhenqiang Sun","doi":"10.1186/s12885-026-16750-4","DOIUrl":"https://doi.org/10.1186/s12885-026-16750-4","url":null,"abstract":"<p><strong>Background: </strong>Dedifferentiated liposarcoma (DDLPS), a rare disease with limited research, exhibits resistance to radiotherapy and chemotherapy. Few reports have analyzed the tumor microenvironment of retroperitoneal undifferentiated liposarcoma using single-cell sequencing.</p><p><strong>Methods: </strong>Single-cell analysis of three retroperitoneal DDLPS cases characterized the cellular and immune microenvironment.</p><p><strong>Results: </strong>Our findings reveal significant heterogeneity among malignant cells in DDLPS, with chromosome 6 deletions being prevalent across malignant cell subpopulations and potentially linked to reduced immunogenicity based on pathway analyses. Notably, the coexistence of CD8 + T cell exhaustion and cytotoxicity reflects a continuum of exhaustion transition. Moreover, we identify a C3 + malignant cell subpopulation with ECM remodeling, angiogenesis, and activated complement pathway. Further exploration suggested that C3 + malignant cells may recruit IL2RA+ regulatory T cells and SPP1 + macrophages through the C3-C3aR1 axis.</p><p><strong>Conclusion: </strong>Our findings provide new insights into the application of immunotherapy in sarcoma.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13695301/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy.","authors":"Shaoyan Lin, Huaqiang Zhou, Gang Chen, Jinhui Xue, Qianwen Liu, Jianing Li, Yanhua Yang, Yuanyuan Zhao, Hua Bao, Yan Huang, Yuxiang Ma, Hongyun Zhao","doi":"10.1186/s12885-026-16657-0","DOIUrl":"10.1186/s12885-026-16657-0","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13464639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148721028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.","authors":"Marie-Kristin Tilch, Christian Schmidt, Marek Trneny, Eva Giné, Olivier Hermine, Anke Ohler, Stephanie Herold, Eva Hoster, Linmiao Jiang, Christiane Pott, Martin Dreyling, Georg Hess","doi":"10.1186/s12885-026-16602-1","DOIUrl":"10.1186/s12885-026-16602-1","url":null,"abstract":"<p><strong>Background: </strong>Brexucabtagene-autoleucel (brexu-cel) is an anti-CD19 chimeric antigen receptor T-cell (CAR-T) product approved for relapsed/refractory Mantle Cell Lymphoma (MCL) after two prior treatment lines, including Bruton tyrosine kinase inhibitors (BTKi). Patients with high-risk (hr) disease-defined by high-intermediate or high-risk MIPI-c, p53 overexpression, or TP53 alterations-have a poor prognosis, underscoring the need for improved first-line strategies. The European Mantle Cell Lymphoma Network therefore designed a phase II trial to investigate the incorporation of brexu-cel into first-line therapy for hr MCL.</p><p><strong>Methods: </strong>CARMAN is a randomized controlled, international, multicenter, open-label phase II trial evaluating efficacy, safety, and tolerability of an abbreviated induction followed by first-line brexu-cel and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B). In Arm A, induction consists of two cycles of ibrutinib plus rituximab (I + R) followed by two cycles of R-CHOP plus ibrutinib (I). R-CHOP + I may be omitted in patients achieving complete or partial remission after two cycles of I + R, who then receive one additional I + R cycle before brexu-cel infusion and I maintenance. Arm B comprises a TRIANGLE-like regimen based on age, fitness, and investigator choice (alternating R-CHOP plus ibrutinib/R-DHAP or IR-bendamustine), followed by IR maintenance. Overall, 150 patients from five European countries are randomized 1:1. The primary endpoint is failure-free survival from randomization, with failure event defined as the earliest of stable disease at the end of induction (Arm B, or Arm A if brexu-cel is not infused) or within 12 weeks from CAR-T-cell infusion (Arm A), disease progression after induction, or death from any cause. Secondary endpoints include efficacy (overall and complete response rates and PET-negative CR rate 6 months from randomization as assessed according to Lugano criteria, molecular remission rate as measured by MRD), safety and tolerability (adverse events graded according to CTCAE), and patient-reported quality of life as measured by the EORTC-QLQ-C30 and EORTC-QLQ-NHL-HG29 questionnaires.</p><p><strong>Discussion: </strong>When complete, CARMAN will provide important information on efficacy and safety in first-line CAR-T cell therapy in hr MCL and has the potential to prepare a practice changing confirmatory trial for these difficult-to-treat patients. Recruitment is ongoing.</p><p><strong>Trial registration: </strong>EU clinical trial number: 2022-502405-15-00.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13459421/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148711502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Co-mutation landscape and prognostic impact of genomic complexity in EGFR-mutant non-small cell lung cancer.","authors":"Xiangdi Yang, Guojian Huang, Kejun Liu, Dongxia Wang, June Wang, Meixia Huang, Linxuan Huang","doi":"10.1186/s12885-026-16715-7","DOIUrl":"https://doi.org/10.1186/s12885-026-16715-7","url":null,"abstract":"<p><strong>Methods: </strong>Clinical and genomic data of patients with EGFR-mutant NSCLC were collected from publicly available cBioPortal cohorts. Cohort composition, stage availability, recurrent co-mutations, and study-origin heterogeneity were evaluated. Patients harboring EGFR Del19 or L858R mutations and available survival information were included for survival analyses. Genomic landscapes were analyzed using a standardized Del19/L858R survival cohort. Survival outcomes were evaluated using Kaplan-Meier curves and Cox regression models, including sensitivity analyses adjusted for study origin and available tumor stage. Co-mutation burden and TP53/ATM-defined DDR-related alterations were further assessed as exploratory prognostic features.</p><p><strong>Results: </strong>A total of 1,024 EGFR-mutant NSCLC patients were identified. Among them, 844 patients harbored Del19 or L858R mutations. Among the 844 patients with EGFR Del19 or L858R mutations, 820 had complete survival information and were included in survival analyses (Del19, n = 429; L858R, n = 391). An apparent OS difference was observed between Del19 and L858R tumors in the pooled cBioPortal cohort; however, this association was attenuated after accounting for study-origin heterogeneity and was therefore interpreted as exploratory. TP53 mutation was the most robust adverse prognostic factor and remained independently associated with inferior survival after adjustment for study origin. PIK3CA mutation also remained associated with poorer OS in the study-origin-adjusted model, whereas EGFR subtype and CDKN2A mutation were not retained as independent prognostic factors after accounting for study-level heterogeneity. Increasing co-mutation burden was associated with progressively shorter OS. TP53/ATM-defined DDR-related alterations were associated with inferior OS in exploratory analysis, but this result was largely driven by TP53 because ATM-only alterations were rare and not significantly associated with OS.</p><p><strong>Conclusion: </strong>Our study demonstrates that prognosis in EGFR-mutant NSCLC is strongly influenced by broader genomic context, particularly TP53 mutation and overall co-mutation burden. EGFR subtype-specific survival differences and TP53/ATM-defined DDR-related findings should be interpreted cautiously because of study-origin heterogeneity, incomplete clinical annotation, and the limited DDR gene definition.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13628935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Establishment and genomic validation of novel patient-derived xenograft models for drug discovery in gastrointestinal stromal tumor.","authors":"Marya Kozinova, Ashot Nazaretian, Martin G Belinsky, Yan Zhou, Shalina Joshi, Karthik Devarajan, Kathy Q Cai, Delia Zumpano, Shuai Ye, Yinfei Tan, Sanjay S Reddy, Jeffrey M Farma, Margaret von Mehren, Lori Rink","doi":"10.1186/s12885-026-16659-y","DOIUrl":"10.1186/s12885-026-16659-y","url":null,"abstract":"<p><p>Most gastrointestinal stromal tumor (GIST) patients develop clinical resistance to approved tyrosine kinase inhibitors (TKI). The development of effective treatment strategies for refractory GIST requires identification of novel targets for investigational agents and well-characterized preclinical models, like patient-derived xenograft (PDX) models, to evaluate them. While GIST PDX models have been shown to mirror patient tumors in cell morphology and driver mutation status, studies across tumor types indicate that PDX models may undergo limited genomic changes during engraftment and passaging. We performed a comprehensive genomic analysis of six KIT-mutant GIST PDX models derived from TKI-refractory patients. Pairwise comparison of copy number variation (CNV) profiles indicated strong correlation between PDX and matched primary tumors. Four models exhibited changes in the number of CNV events relative to the primary tumors, suggesting clonal selection and tumor heterogeneity during engraftment and passaging. Analysis of cancer-associated gene aberrations showed stability of primary KIT driver mutations, with minor fluctuations in the allelic frequencies of acquired mutations, suggesting initial heterogeneity of GIST tumors and potential enrichment of sub-clonal populations through passaging. To functionally assess model fidelity in vivo, three PDX models were treated with the approved second-line TKI sunitinib. The models exhibited differential responses that could not be fully explained by driver mutation status alone, highlighting the need for further investigation in larger cohorts.These findings highlight the importance of comprehensive genomic characterization of PDX models prior to their use in preclinical studies, supporting more accurate interpretation of experimental results and preserving their value as research tools.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13654211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149163687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial expression of concern (EEoC): Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts.","authors":"Chi Man Tsang, Yuk Chun Cheung, Vivian Wai-Yan Lui, Yim Ling Yip, Guitao Zhang, Victor Weitao Lin, Kenneth Chat-Pan Cheung, Yibin Feng, Sai Wah Tsao","doi":"10.1186/s12885-026-16706-8","DOIUrl":"10.1186/s12885-026-16706-8","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13455245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148700782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α₂M.","authors":"Song Zhao, Hongdan Li, Qingjun Wang, Chang Su, Guan Wang, Huijuan Song, Liang Zhao, Zhidong Luan, Rongjian Su","doi":"10.1186/s12885-026-16695-8","DOIUrl":"10.1186/s12885-026-16695-8","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148696985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction Note: Blockage of AMPK-ULK1 pathway mediated autophagy promotes cell apoptosis to increase doxorubicin sensitivity in breast cancer (BC) cells: an in vitro study.","authors":"Libo Yu, Qingtao Shi, Yan Jin, Zhixin Liu, Jiaxin Li, Wenzhou Sun","doi":"10.1186/s12885-026-16663-2","DOIUrl":"10.1186/s12885-026-16663-2","url":null,"abstract":"","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"26 1","pages":""},"PeriodicalIF":4.1,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13453079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148697032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}